Discover
TARS
Tarsus Pharmaceuticals, Inc.
60.89
1 x 59.79
2 x 73.21
bid
ask
-
2.05
3.26%
2 @ 04:00 PM
60.89 +0.00 (0.00%)
| Ytd | -25.64% | |
| 1y | 52.26% |
56.57
day range
65.82
38.51
52 week range
85.25
| Open | 63.91 | Prev Close | 62.94 | Low | 56.57 | High | 65.82 | Mkt Cap | 2.62B |
| Vol | 2.45M | Avg Vol | 722.51K | EPS | -1.11 | P/E | N/A | Forward P/E | 21.24 |
| Beta | 0.51 | Short Ratio | 7.92 | Inst. Own | 109.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 62.14 | 200-d Avg | 68.60 | 1yr Est | 94.11 |
| Income Statement | |||
| Total Revenue | 162.05M | ||
| Revenues (USD) | 162.05M | ||
| Cost of Revenue | 9.40M | ||
| Gross Profit | 152.66M | ||
| Operating Expenses | 158.78M | ||
| Research and Development Expense | 22.35M | ||
| Selling, General and Administrative Expense | 136.43M | ||
| Operating Income | -6.12M | ||
| Interest Expense | 2.13M | ||
| Income Tax Expense | 2.35M | ||
| Net Income | -6.97M | ||
| Net Income Common Stock | -6.97M | ||
| Net Income Common Stock (USD) | -6.97M | ||
| Consolidated Income | -6.97M | ||
| Earnings per Basic Share | -0.16 | ||
| Earnings per Basic Share (USD) | -0.16 | ||
| Earnings per Diluted Share | -0.16 | ||
| Earning Before Interest & Taxes (EBIT) | -2.49M | ||
| Earning Before Interest & Taxes (USD) | -2.49M | ||
| Weighted Average Shares | 42.96M | ||
| Weighted Average Shares Diluted | 42.96M | ||
| Balance Sheet | |||
| Cash and Equivalents | 102.19M | ||
| Cash and Equivalents (USD) | 102.19M | ||
| Investments | 292.41M | ||
| Investments Current | 286.54M | ||
| Investments Non-Current | 5.87M | ||
| Trade and Non-Trade Receivables | 117.21M | ||
| Current Assets | 537.23M | ||
| Property, Plant & Equipment Net | 27.67M | ||
| Total Assets | 581.14M | ||
| Total Debt | 72.60M | ||
| Current Liabilities | 143.51M | ||
| Debt Non-Current | 72.60M | ||
| Total Liabilities | 232.18M | ||
| Accumulated Retained Earnings (Deficit) | -433.59M | ||
| Accumulated Other Comprehensive Income | -298.00K | ||
| Shareholders Equity | 348.95M | ||
| Shareholders Equity (USD) | 348.95M | ||
| Assets Non-Current | 43.91M | ||
| Total Debt (USD) | 72.60M | ||
| Goodwill and Intangible Assets | 7.13M | ||
| Inventory | 7.10M | ||
| Liabilities Non-Current | 88.68M | ||
| Trade and Non-Trade Payables | 24.13M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 514.00K | ||
| Net Cash Flow from Financing | 1.20M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -82.01M | ||
| Capital Expenditure | -5.82M | ||
| Issuance (Purchase) of Equity Shares | 1.20M | ||
| Net Cash Flow from Investing | -58.56M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -52.74M | ||
| Net Cash Flow from Operations | -24.65M | ||
| Share Based Compensation | 11.97M | ||